Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Iterum Therapeutics plc (NASDAQ:ITRM), a pharmaceutical company, announced on Monday that its subsidiary, Iterum Therapeutics US Limited ("ITUS"), has entered into a Product Commercialization Agreement with EVERSANA Life Science Services, LLC ("Eversana"). The agreement, signed on June 6, 2025, outlines Eversana’s commitment to provide a range of services for the commercialization of Iterum’s approved product, ORLYNVAH™, in the United States.
The services provided by Eversana will include sales and commercial operations, marketing, logistics, channel management, regulatory, medical affairs, and other related activities. ITUS will retain responsibilities for legal, regulatory, and manufacturing aspects of ORLYNVAH™ and will record sales in the U.S.
The partnership terms dictate that ITUS will compensate Eversana for its services and related expenses as per agreed statements of work. The agreement grants Eversana exclusive rights to provide the agreed services, with the arrangement set to last for five years from the commercial launch of ORLYNVAH™.
Both parties have the right to terminate the agreement under certain conditions, including material breaches, insolvency, changes in law, safety recalls, or decline in sales. Additionally, termination rights are extended following a change of control at ITUS or Iterum, with stipulated termination fees payable to Eversana.
The agreement includes standard provisions to protect confidential information and intellectual property, along with customary insurance, indemnification, and limitations of liability clauses. Further details of the agreement will be disclosed in Iterum Therapeutics plc’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.
This news is based on information contained in a recent SEC filing by Iterum Therapeutics plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.